Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
TWST proposed sales of common stock by an insider under a Form 144 notice. The excerpt lists four reported transactions by Adam Laponis: 7,000 shares on 02/12/2026 for $350,000, 2,085 shares on 02/23/2026 for $97,389.93, 2,597 shares on 04/09/2026 for $129,561.48, and 3,000 shares on 04/14/2026 for $165,000. The filing also lists scheduled issuances from restricted stock vesting and an ESPP purchase on specified dates.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported an open-market sale of 3,000 shares of common stock at $55.00 per share. The transaction was made under a previously adopted Rule 10b5-1 trading plan. Following this sale, he continues to hold 122,694 shares directly.
Company filed a Form 144 disclosing proposed resale of Common Stock and recent insider sales. The filing lists three reported sales by Adam Laponis: 7,000 shares on 02/12/2026 for $350,000.00, 2,085 shares on 02/23/2026 for $97,389.93, and 2,597 shares on 04/09/2026 for $129,561.48. The notice also records recent issuances to Fidelity/employee plans: 345 shares (ESPP) and restricted stock vestings of 564 and 2,091 shares on the listed dates.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans, and were not discretionary trades. After this transaction, Laponis directly holds 125,694 shares of Twist Bioscience common stock.
TWST filed a Form 144 proposing the sale of 2,597 shares of Common Stock. The filing lists the planned sale as arising from Restricted Stock Vesting with an issuer-directed disposition dated 04/08/2026. The notice also reports four sales in the past three months: 2,738, 3,000, 7,000, and 2,085 shares on 01/09/2026, 01/13/2026, 02/12/2026, and 02/23/2026, respectively.
Twist Bioscience director Melissa A. Starovasnik executed an open-market sale of 1,000 shares of Common Stock at $51.00 per share on April 1, 2026. After the transaction, she directly holds 25,722 shares of Twist Bioscience common stock.
The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the transaction was planned in advance rather than timed discretionarily.
The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting 03/13/2026 activity for Twist Bioscience Corp common stock. The filing states that, after an internal realignment effective 01/12/2026, certain Vanguard subsidiaries will report ownership separately under SEC Release No. 34-39538. The filing shows amount beneficially owned: 0 and percent of class: 0%. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Twist Bioscience Corp officer Dennis Cho reported a mandated sale of 354 shares of Common Stock at $43.7864 per share to cover tax withholding on vesting Restricted Stock Units. After this sell-to-cover transaction, Cho directly holds 137,903 Twist Bioscience shares.
Twist Bioscience Corp senior vice president of human resources Paula Green reported a small sale of common stock tied to taxes on vested Restricted Stock Units. She sold 297 shares at an average price of $43.7864 per share through a mandated “sell to cover” transaction under the company’s equity incentive plans. After this tax-related sale, she directly holds 124,104 shares of Twist Bioscience common stock. The footnote explains that the transaction was required to satisfy tax withholding obligations and did not reflect a discretionary trading decision by the executive.